Dissertation/Thesis Abstract

Harmine-Based Therapies to Promote Beta Cell Regeneration
by Zlatanic, Viktor, M.S., Icahn School of Medicine at Mount Sinai, 2019, 64; 13903928
Abstract (Summary)

Diabetes is a disease diagnosed by the inability to regulate blood glucose concentration. A primary cause of diabetes is loss of insulin-producing pancreatic cells, or beta cells, which permanently affects insulin production capacity. For this reason, small molecules that can induce healthy, endogenous beta cell proliferation and regeneration have become the subject of vigorous research as of late. Studies in this thesis indicate that dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors such as harmine and harmine-derived analogs, or “harmalogs,” promote beta cell replication in mouse and human islets in vivo. Furthermore, co-treatment with harmine and transforming growth factor beta (TGF-beta) inhibitors further induce robust beta cell proliferation in vivo. These results suggest a potential future therapy for promoting beta cell regeneration and the recovery of glycemic control in diabetic patients.

Indexing (document details)
Advisor: Garcia Ocaña, Adolfo
Commitee: Vasavada, Rupangi, Scott, Donald
School: Icahn School of Medicine at Mount Sinai
Department: Biomedical Sciences
School Location: United States -- New York
Source: MAI 81/2(E), Masters Abstracts International
Source Type: DISSERTATION
Subjects: Medicine, Biology, Nutrition
Keywords: Beta cell, Diabetes, DYRK1A, Harmalog, Harmine
Publication Number: 13903928
ISBN: 9781085590778
Copyright © 2019 ProQuest LLC. All rights reserved. Terms and Conditions Privacy Policy Cookie Policy
ProQuest